Included in the formulation
АТХ:S.01.E.E.05 Tafluprost
Pharmacodynamics:Fluorinated analogue of prostaglandin F2α, a selective FP receptor agonist. Increases the outflow of moisture along the uveoscleral pathway, reducing intraocular pressure. The effect of the drug begins 3-4 hours after the injection, the maximum effect develops after 8-12 hours. Duration of action is 24 hours.
Pharmacokinetics:Free penetrates through the cornea, hydrolyzed to a biologically active form. The maximum concentration in aqueous humor occurs 2 hours after topical application.
The half-life is 17 minutes.
Indications:It is used to reduce intraocular pressure in patients with elevated ophthalmotonus and open-angle glaucoma.
VII.H40-H42.H40.0 Suspicion of glaucoma
VII.H40-H42.H40.1 Primary open angle glaucoma
Contraindications:Bronchial asthma (including history), chronic heart failure II and III degree, atrioventricular block II-III degree, cardiogenic shock, children under 18 years of age.
Individual intolerance.
Carefully:
Afakia, pseudofakiya. Congenital, inflammatory, neovascular forms of glaucoma. Diabetes mellitus, thyrotoxicosis, myasthenia gravis.
Pregnancy and lactation:Contraindicated in pregnancy and lactation.
Dosing and Administration:1 drop once a day in a conjunctival sac at night.
Side effects:Eye irritation: itching, sensation of foreign body, congestion hyperemia. Increased pigmentation of the iris, macular edema, blurred vision.
Allergic reactions.
Overdose:Hyperemia of the eyes and eyelids.
Treatment is symptomatic.
Interaction:Mydriasum with simultaneous application with epinephrine.
Special instructions:Before using the drug, the patient should be warned about irreversible changes in eye color, darkening of the eyelid skin, changes in thickness, length and number of eyelashes, especially if one eye is treated.
Persons using contact eye correction should wear the lenses no earlier than 15 minutes after instillation.